Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06205121 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

A Phase 2 study of Pulmonary Sarcoidosis, sponsored by Molecure S.A..

Recruiting
Registry status
Phase 2
Development phase
96
Enrollment target
20
Study locations

NCT06205121 is a Phase 2 study of Pulmonary Sarcoidosis that is actively recruiting participants, run by Molecure S.A.. The registered enrollment target is 96 participants, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06205121, a Phase 2 study of Pulmonary Sarcoidosis, is actively recruiting participants, sponsored by Molecure S.A..

RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

Conditions Studied

Pulmonary Sarcoidosis

Interventions

  • DRUG Placebo
  • DRUG OATD-01

Study Locations (20)

Other

  • Molecure Investigative Site - Vejle
  • Molecure Investigative Site - Bobigny
  • Molecure Investigative Site - Montpellier
  • Molecure Investigative Site - Paris
  • Molecure Investigative Site - Paris
  • Molecure Investigative Site - Essen
  • Molecure Investigative Site - Freiburg im Breisgau
  • Molecure Investigative Site - Mainz-GE
  • Molecure Investigative Site - Corfu
  • Molecure Investigative Site - Heraklion
  • Molecure Investigative Site - Pátrai
  • Molecure Investigative Site - Thessaloniki
  • Molecure Investigative Site - Nieuwegein

Alabama

  • Molecure Investigative Site - Birmingham

Kansas

  • Molecure Investigative Site - Kansas City

Maryland

  • Molecure Investigative Site - Baltimore

Minnesota

  • Molecure Investigative Site - Rochester

Ohio

  • Molecure Investigative Site - Cleveland

Pennsylvania

  • Molecure Investigative Site - Philadelphia

South Carolina

  • Molecure Investigative Site - Charleston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2024-03-21
Est. Completion 2027-09
Phase Phase 2

Sponsor

Molecure S.A.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06205121

The ClinicalTrials.gov registry entry for NCT06205121 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower). The listed sponsor is Molecure S.A., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06205121 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Alabama, Kansas.

Frequently Asked Questions

What is clinical trial NCT06205121 about?

NCT06205121 is a clinical study titled "Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis". This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

What is the current status of trial NCT06205121?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2024-03-21. Estimated completion is 2027-09.

What conditions does trial NCT06205121 study?

This clinical trial studies the following conditions: Pulmonary Sarcoidosis.

What interventions are being tested in trial NCT06205121?

The interventions under investigation include: Placebo (DRUG), OATD-01 (DRUG).

Who is sponsoring clinical trial NCT06205121?

This trial is sponsored by Molecure S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06205121 being conducted?

This trial has 20 study locations across Alabama, Kansas, Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Sarcoidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Sarcoidosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.